Across TCGA pan-cancer cohorts, LINC02136 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of LINC02136’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where LINC02136 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC02136 is over-expressed in tumor.
PRAD and LUAD are the cancer types where LINC02136 tumor–normal differential expression is most reproducible.